140 related articles for article (PubMed ID: 25588041)
1. Cell cycle control as a promising target in melanoma.
Lee B; Sandhu S; McArthur G
Curr Opin Oncol; 2015 Mar; 27(2):141-50. PubMed ID: 25588041
[TBL] [Abstract][Full Text] [Related]
2. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
3. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma.
Sheppard KE; McArthur GA
Clin Cancer Res; 2013 Oct; 19(19):5320-8. PubMed ID: 24089445
[TBL] [Abstract][Full Text] [Related]
4. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
[No Abstract] [Full Text] [Related]
5. Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas.
Bachmann IM; Straume O; Akslen LA
Int J Oncol; 2004 Dec; 25(6):1559-65. PubMed ID: 15547691
[TBL] [Abstract][Full Text] [Related]
6. Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.
Xu L; Cheng Z; Cui C; Wu X; Yu H; Guo J; Kong Y
J Transl Med; 2019 Jul; 17(1):245. PubMed ID: 31358010
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
Fåhraeus R; Laín S; Ball KL; Lane DP
Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Konecny GE
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):42-8. PubMed ID: 26642065
[TBL] [Abstract][Full Text] [Related]
9. Cell Cycle Regulation and Melanoma.
Xu W; McArthur G
Curr Oncol Rep; 2016 Jun; 18(6):34. PubMed ID: 27106898
[TBL] [Abstract][Full Text] [Related]
10. Targeting CDK4/6 in patients with cancer.
Hamilton E; Infante JR
Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
[TBL] [Abstract][Full Text] [Related]
11. Mutation testing in melanoma families: INK4A, CDK4 and INK4D.
Newton Bishop JA; Harland M; Bennett DC; Bataille V; Goldstein AM; Tucker MA; Ponder BA; Cuzick J; Selby P; Bishop DT
Br J Cancer; 1999 Apr; 80(1-2):295-300. PubMed ID: 10390011
[TBL] [Abstract][Full Text] [Related]
12. Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding.
Becker TM; Rizos H; Kefford RF; Mann GJ
Clin Cancer Res; 2001 Oct; 7(10):3282-8. PubMed ID: 11595726
[TBL] [Abstract][Full Text] [Related]
13. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE
Pigment Cell Melanoma Res; 2014 Jul; 27(4):590-600. PubMed ID: 24495407
[TBL] [Abstract][Full Text] [Related]
14. Genes involved in melanoma: an overview of INK4a and other loci.
Castellano M; Parmiani G
Melanoma Res; 1999 Oct; 9(5):421-32. PubMed ID: 10596908
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways: CDK4 inhibitors for cancer therapy.
Dickson MA
Clin Cancer Res; 2014 Jul; 20(13):3379-83. PubMed ID: 24795392
[TBL] [Abstract][Full Text] [Related]
16. Expression of the cell-cycle regulatory proteins (pRb, cyclin D1, p16INK4A and cdk4) in human endometrial cancer: correlation with clinicopathological features.
Semczuk A; Miturski R; Skomra D; Jakowicki JA
Arch Gynecol Obstet; 2004 Jan; 269(2):104-10. PubMed ID: 14648178
[TBL] [Abstract][Full Text] [Related]
17. Sequential extension of proliferative lifespan in human fibroblasts induced by over-expression of CDK4 or 6 and loss of p53 function.
Morris M; Hepburn P; Wynford-Thomas D
Oncogene; 2002 Jun; 21(27):4277-88. PubMed ID: 12082615
[TBL] [Abstract][Full Text] [Related]
18. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
McKenzie HA; Fung C; Becker TM; Irvine M; Mann GJ; Kefford RF; Rizos H
Hum Mutat; 2010 Jun; 31(6):692-701. PubMed ID: 20340136
[TBL] [Abstract][Full Text] [Related]
19. Regulation of cyclin-dependent kinase 4 during adipogenesis involves switching of cyclin D subunits and concurrent binding of p18INK4c and p27Kip1.
Phelps DE; Xiong Y
Cell Growth Differ; 1998 Aug; 9(8):595-610. PubMed ID: 9716177
[TBL] [Abstract][Full Text] [Related]
20. Activation of a cAMP pathway and induction of melanogenesis correlate with association of p16(INK4) and p27(KIP1) to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes.
Haddad MM; Xu W; Schwahn DJ; Liao F; Medrano EE
Exp Cell Res; 1999 Dec; 253(2):561-72. PubMed ID: 10585280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
